Bristol-Myers Squibb Company

NYSE:BMY

Drug Manufacturers - General

Healthcare
$59.56 -2.57%

-$1.42 today

Market cap
$121.75B
Beta
0.24
P/E (TTM)
15.1
EPS (TTM)
$3.56
Dividend yield
4.64%
52W Low $42.52High $62.89

Volume 9.54M

Average 11.50M

BMY Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Bristol-Myers Squibb CompanyNYSE: BMY

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to 25.6%

Net margin was 25.6% in Q2 FY2026, up 14.9 pp from a year earlier. On a trailing-twelve-month basis it was 18.9%, up 8.3 pp year over year. Over 3 fiscal years it widened by 0.9 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 19 analysts of 26.3% for the fiscal year ending Dec 2026, up from 14.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
25.6%+2.3 pp QoQ
Last fiscal yearDec 2025
14.6%+33.2 pp YoY
LTMJun 2026
18.9%+8.3 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.9 pp-0.3 pp-15.2 pp
1 year+33.2 pp+11.7 pp-21.5 pp
3 years+0.9 pp+12.3 pp+11.4 pp
5 years+12.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
14.6%
Year-over-year change
+33.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How BMY compares with its peers on the latest reported figures

  • BMY's LTM Jun 2026 net margin of 18.9% is the 4th highest of the 11 companies compared; the peer median is 15.9%.
  • Its year-over-year change of +8.3 pp is the 2nd highest of 11, against a peer median of -0.2 pp.
  • Over three fiscal years its change of +0.9 pp compares with a peer median of +4.8 pp.
BMY Competitors Peer median
Net Margin for BMY and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202633.5% +7.6 pp+9.8 pp
NVSNovartis AGLTM Jun 202622.9% -1.8 pp+9.6 pp
AMGNAmgen Inc.LTM Jun 202622.9% +4.0 pp-3.9 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202618.9% +8.3 pp+0.9 pp
AZNAstraZeneca PLCLTM Sep 202617.7% +1.5 pp+10.0 pp
JNJJohnson & JohnsonLTM Sep 202616.2% -11.1 pp+6.0 pp
ABBVAbbVie Inc.LTM Sep 202615.7% +11.7 pp-13.5 pp
GSKGSK plcLTM Jun 202614.5% +3.7 pp-33.5 pp
PFEPfizer Inc.LTM Jun 20266.8% -10.0 pp-18.6 pp
MRKMerck & Co., Inc.LTM Jun 20264.8% -21.0 pp+3.6 pp
GILDGilead Sciences, Inc.LTM Jun 2026-10.6% -32.5 pp+12.1 pp
Peer median (excluding BMY) 15.9%-0.2 pp+4.8 pp

Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue46.39B46.16B45.01B48.3B48.2B
Cost of Revenue9.94B10.14B10.69B13.97B13.94B
Gross Profit36.45B36.02B34.31B34.33B34.26B
Gross Margin78.6%78.0%76.2%71.1%71.1%
Research & Development10.2B9.51B9.3B11.16B9.95B
Selling, General & Admin7.69B7.81B7.77B8.41B7.27B
Operating Expenses27.91B26.92B26.12B28.45B20.54B
Depreciation & Amortization10.69B10.28B9.76B9.6B4.01B
EBITDA20.12B19.22B19.37B3.17B15.23B
EBITDA Margin43.4%41.6%43.0%6.6%31.6%
Operating Income8.54B9.1B8.2B5.89B13.72B
Operating Margin18.4%19.7%18.2%12.2%28.5%
Interest Income00000
Interest Expense1.33B1.23B1.17B1.95B1.89B
Other Income / Expenses(439M)(1.39B)245M(14.27B)(4.4B)
Income Before Tax8.1B7.71B8.44B(8.38B)9.33B
Pre-Tax Margin17.5%16.7%18.8%-17.3%19.4%
Income Tax Expense1.08B1.37B400M554M2.27B
Net Income6.99B6.33B8.03B(8.95B)7.05B
Net Margin15.1%13.7%17.8%-18.5%14.6%
EPS (Basic)3.152.973.88(4.41)3.46
EPS (Diluted)3.122.953.86(4.41)3.45
Weighted Avg Shares2.22B2.13B2.07B2.03B2.04B
Weighted Avg Shares (Diluted)2.25B2.15B2.08B2.03B2.04B

Bristol-Myers Squibb Company

NYSE:BMY

Intrinsic Alpha fair value

Locked

Current Price

$59.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.